相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Villar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding et al.
LANCET (2014)
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Jorge E. Osorio et al.
LANCET INFECTIOUS DISEASES (2014)
A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
Anna P. Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Reduced Risk of Disease During Postsecondary Dengue Virus Infections
Sandra Olkowski et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
The global distribution and burden of dengue
Samir Bhatt et al.
NATURE (2013)
Identifying protective dengue vaccines: Guide to mastering an empirical process
Scott B. Halstead
VACCINE (2013)
Identification of Dengue Fever Cases in Houston, Texas, with Evidence of Autochthonous Transmission Between 2003 and 2005
Kristy O. Murray et al.
VECTOR-BORNE AND ZOONOTIC DISEASES (2013)
Chikungunya and dengue autochthonous cases in Europe, 2007-2012
Danilo Tomasello et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2013)
Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
Claire Y. -H. Huang et al.
PLOS NEGLECTED TROPICAL DISEASES (2013)
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon et al.
LANCET (2012)
Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice
Joseph N. Brewoo et al.
VACCINE (2012)
Dengue and US Military Operations from the Spanish-American War through Today
Robert V. Gibbons et al.
EMERGING INFECTIOUS DISEASES (2012)
Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques
Jorge E. Osorio et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever
Jorge E. Osorio et al.
VACCINE (2011)
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
Rosario Z. Capeding et al.
VACCINE (2011)
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
Bruno Guy et al.
VACCINE (2011)
Replication of the Primary Dog Kidney-53 Dengue 2 Virus Vaccine Candidate in Aedes aegypti Is Modulated by a Mutation in the 5′ Untranslated Region and Amino Acid Substitutions in Nonstructural Proteins 1 and 3
Aaron C. Brault et al.
VECTOR-BORNE AND ZOONOTIC DISEASES (2011)
A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial
Anna P. Durbin et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults
Wellington Sun et al.
HUMAN VACCINES (2009)
Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses
John T. Roehrig et al.
VIRAL IMMUNOLOGY (2008)
Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA
S Butrapet et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development
CYH Huang et al.
JOURNAL OF VIROLOGY (2003)
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
N Kanesa-thasan et al.
VACCINE (2001)
Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3
S Butrapet et al.
JOURNAL OF VIROLOGY (2000)
Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
CYH Huang et al.
JOURNAL OF VIROLOGY (2000)
分享论文
